menu
    • menu

    Company profile for Coeptis Therapeutics

    NEW Drugs in Dev: 2
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Coeptis Therapeutics, Inc. was previously named Vinings Holdings, Inc., and became Coeptis Therapeutics by way of a name change on July 12, 2021. Coeptis Therapeutics, with its subsidiary Coeptis Pharmaceuticals, focuses on the development and/or acquisition of pharmaceutical products which offer improvements to current therapies, thereby, improving patient outcomes.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Coeptis TherapeuticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    105 Bradford Road, Suite 420, Wexford, PA 15090
    Telephone
    Telephone
    +1 (724) 934-6467
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://coeptistx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Z Squared Completes Merger with Coeptis, Lists on Nasdaq
    Z Squared Completes Merger with Coeptis, Lists on Nasdaq

    26 Apr 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7209579

    FIRSTWORD PHARMA
    26 Apr 2026
    Share Share
    Coeptis Approves Z Squared Inc.'s Nasdaq Listing Application
    Coeptis Approves Z Squared Inc.'s Nasdaq Listing Application

    07 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/07/3269492/0/en/Coeptis-Announces-Approval-of-Z-Squared-Inc-s-Nasdaq-Listing-Application.html

    GLOBENEWSWIRE
    07 Apr 2026
    Share Share
    Coeptis Receives Shareholder Approval Towards Z Squared Merger
    Coeptis Receives Shareholder Approval Towards Z Squared Merger

    05 Feb 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/02/05/3233404/0/en/Coeptis-Receives-Shareholder-Approval-Towards-Z-Squared-Merger.html

    GLOBENEWSWIRE
    05 Feb 2026
    Share Share
    Coeptis Therapeutics S-4 Declared Effective by SEC
    Coeptis Therapeutics S-4 Declared Effective by SEC

    06 Jan 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/01/06/3213607/0/en/Coeptis-Therapeutics-S-4-Declared-Effective-by-SEC-Proxy-Mailing-Begins-in-Anticipation-of-the-Merger-Transaction-with-Z-Squared.html

    GLOBENEWSWIRE
    06 Jan 2026
    Share Share
    Coeptis Secures $800M Valuation With Dual-Sector Strategy
    Coeptis Secures $800M Valuation With Dual-Sector Strategy

    01 Oct 2025

    // ACCESSWIRE

    https://www.accessnewswire.com/newsroom/en/biotechnology/coeptis-anchors-800m-valuation-in-dual-sector-strategy-vanderbilt-report-publishes-co-1080506

    ACCESSWIRE
    01 Oct 2025
    Share Share
    Coeptis Demonstrates Biotech's Self-Funding Innovation Ability
    Coeptis Demonstrates Biotech's Self-Funding Innovation Ability

    23 Sep 2025

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2025/09/23/3154600/0/en/Vanderbilt-Report-Coeptis-Shows-How-Biotech-Can-Fund-Itself-While-Innovating.html

    GLOBENEWSWIRE
    23 Sep 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search